Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Down 1.9% – Should You Sell?
by Michael Walen · The Markets DailyEupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report)’s share price traded down 1.9% during trading on Thursday . The company traded as low as C$6.69 and last traded at C$6.72. 82,431 shares traded hands during mid-day trading, an increase of 1,012% from the average session volume of 7,410 shares. The stock had previously closed at C$6.85.
Eupraxia Pharmaceuticals Stock Performance
The company has a 50 day moving average price of C$8.00 and a two-hundred day moving average price of C$6.96.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals, Inc (OTCMKTS:EPRXF) is a clinical-stage biotechnology company advancing adeno-associated virus (AAV)-based gene therapies for rare inherited metabolic disorders. The firm’s research platform focuses on developing single-administration treatments designed to address the underlying genetic causes of enzyme deficiencies. Eupraxia’s approach leverages targeted gene delivery to restore or supplement critical metabolic functions in patients with life-threatening conditions.
The company’s lead pipeline candidates include EPRX-101 for Ornithine Transcarbamylase (OTC) deficiency and EPRX-102 for methylmalonic acidemia (MMA), both of which are in preclinical or IND-enabling stages.